Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hua Medicine in Hong Kong IPO Queue; Plans to Raise $400 Million

publication date: Mar 9, 2018

Hua Medicine of Shanghai is planning a $400 million IPO in Hong Kong to fund the company's diabetes drug, dorzagliatin, a novel oral diabetes 2 treatment. In January of this year, Hua's founder and CEO, Chen Li, said Hua would need $200 million over the next three years to complete development and commercialize the drug. Hua expects to be approved to market dorzagliatin in China during 2020. Like several other biopharmas, Hua will take advantage of new Hong Kong Exchange rules that allow not-yet-profitable biopharmas to list on the exchange. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here